Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2832 - A multicentre, Phase II Study with Cabazitaxel in Previously Treated Patients with Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach (CABAGAST)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Oesophageal Cancer;  Gastric Cancer


Thorsten Götze


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


T.O. Götze1, S. Al-Batran1, T. Zander2, A. Reichart1, U. Lindig3, M. Kleiss4, L. Mueller5, C. Bolling6, T. Seufferlein7, P. Reichardt8, F. Kullmann9, H. Eschenburg10, A. Schmittel11, M. Egger12, A. Block13, C. Pauligk14, H. Schmalenberg15

Author affiliations

  • 1 Institute Of Clinical Cancer Research (ikf), Nordwest-Krankenhaus, 60488 - Frankfurt am Main/DE
  • 2 Department 1 For Internal Medicine, , University Hospital Cologne, Cologne/DE
  • 3 Department Of Interdisciplinary Oncology, University Hospital Jena, Friedrich-Schiller-University, 7740 - Jena/DE
  • 4 Dept. Of Oncology, Rotes Kreuz Krankenhaus Kassel, 34129 - Kassel/DE
  • 5 Dept. Of Oncology, Onkologische Schwerpunktpraxis Leer-Emden, 26789 - Leer/DE
  • 6 Dept. Of Oncology, Kliniken Markus-Krankenhaus, Agaplesion, 60431 - Frankfurt am Main/DE
  • 7 Department Of Internal Medicine I  , Ulm University, Ulm/DE
  • 8 Interdisziplinäre Onkologie, HELIOS Klinikum Berlin-Buch, Berlin-Buch/DE
  • 9 Department Of Internal Medicine I, Academic Teaching Hospital Weiden, Weiden/DE
  • 10 Dept. Of Oncology, Internist, 18273 - Güstrow/DE
  • 11 Dept. Of Oncology, Schwerpunkt Hamatologie und Onkologie - Berlin Facharzt für Innere Medizin, Berlin/DE
  • 12 Dept. Of Oncology, Ortenau Klinikum Lahr Medizin Klinik, 77933 - Lahr/DE
  • 13 Dept. Of Oncology, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, 20246 - Hamburg/DE
  • 14 Institute Of Clinical Cancer Research (ikf), Uct-university Cancer Center, Krankenhaus Nordwest, Frankfurt/DE
  • 15 Iv. Medizinische Klinik, Städtisches Krankenhaus Dresden, Dresden/DE


Abstract 2832


This is a single-arm study (NCT01956149) to determine prolonged ( > =4 months) disease control rate with cabazitaxel administered in second- (or later) setting for patients with advanced or metastatic adenocarcinoma of the esophagogastric junction (EGJ) and stomach.


65 patients with advanced EGJ and stomach cancer were treated with 20mg/m2 Cabazitaxel every 3 weeks for a maximum of 6 cycles. Main objective of the study was a prolonged Disease Control Rate (pDCR: CR, PR or SD lasting at least 4 months). Secondary Outcome Measures were overall survival (OS), progression-free survival (PFS), response rate by subgroup (with vs without previous treatment with a taxane) and toxicity. Patients were assessed for tumor response every 6 weeks during therapy and during follow-up (up to 12 months).


65 patients (median age: 63, range 31-86 years) were assigned to treatment. Median no. of prior therapies was 2. 80% had received prior taxane therapy. Patients received a median of 2 cycles of cabazitaxel. Efficacy results are for the per protocol (PP) population. pDCR was 12.7%, (95%CI: 5.3%- 24.5%). pDCR was 20.0% in 2nd line patients (95%CI: 6.8%-40.7%) and 30.0% (95%CI: 6.7%-65.2%) in all lines in patients without prior taxane use. Response rate was 5.5% (95%CI: 1.1%-15.1%) in total PP and 20.0% in the population without prior taxane use. Median OS was 4.6 months (7.4 months without prior taxane vs 3.8 months with prior taxane). Median PFS was 1.38 months (95%CI: 1.28- 1.87) with and 2.01 months (95%CI: 0.20- 4.67) without prior taxane use. Most common grade 3/4 toxicities were neutropenia in 13% of the patients, pain (12%), leucopenia (10%), anemia (10%), fatigue (10%) and nausea (10%).


Cabazitaxel is active in heavily pretreated patients with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Toxicity is moderate. Patients without prior taxane use derived more benefit from Cabazitaxel.

Clinical trial identification


Legal entity responsible for the study

Institute of Clinical Cancer Research




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.